Printer Friendly

3TC ACTIVE AGAINST HEPATITIS B VIRUS

 3TC ACTIVE AGAINST HEPATITIS B VIRUS
 LAVAL, Quebec, March 13 /PRNewswire/ -- BioChem Pharma Inc.


(NASDAQ: BCHXF; Toronto, Montreal: BCH) today announced that the compound 3TC, which is currently in human clinical trials as a potential AIDS treatment, has been found active against the Hepatitis B virus.
 Scientists at the 5th International Conference on Anti-viral research in Vancouver yesterday presented results on the activity of 3TC against Hepatitis B in vitro and in different animal models. In particular, 3TC has been reported to be active in primates infected with human Hepatitis B virus.
 Under BioChem's master license agreement with Glaxo Group Limited, Glaxo is currently conducting pre-clinical evaluation of 3TC as a potential treatment for Hepatitis B. An IND (Investigative New Drug) application for clinical trials is planned for the second quarter of this year.
 BioChem Pharma Inc. is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases.
 -0- 3/13/92
 /CONTACT: Francesco Bellini, president and chief executive officer of BioChem Pharma, 514-681-1744, or Luc Beauregard or Michele Roy of NATIONAL Public Relations, 514-843-7171, for BioChem Pharma/
 (BCHXF) CO: BioChem Pharma Inc.; Glaxo Group Limited ST: Quebec, British Columbia IN: MTC SU:


GK-TS -- NY012 -- 7683 03/13/92 09:21 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 13, 1992
Words:214
Previous Article:LOUIS R. HUGHES NAMED VICE PRESIDENT OF GENERAL MOTORS
Next Article:U.S. SEN. SPECTER'S AMENDMENT TO STIMULATE THE ECONOMY IS ACCEPTED INTO THE TAX BILL
Topics:


Related Articles
How to bring an idea to market.
TRIANGLE PHARMACEUTICALS ACQUIRES EXCLUSIVE RIGHTS TO THREE ANTIVIRAL COMPOUNDS
Vertex Pharmaceuticals Researchers Report Three-Dimensional Structure of Hepatitis C Protease Enzyme; Report in Cell
New Studies with Crixivan Presented at ICAAC: Crixivan in Triple Therapy Lowered HIV to Undetectable Levels for Two Years in Approximately 80 Percent...
Triangle Pharmaceuticals Reports Data on Initial Results of FTC Phase I/II Trial
BIOCHEM PHARMA RECEIVES GO-AHEAD FROM U.S. FDA TO START PHASE I CLINICAL TRIAL WITH ITS NOVEL ANTI-HIV COMPOUND, BCH-10652
Nabi(R) Presents Positive Preclinical Efficacy Data with Staph Drug And with Novel Antiviral Drug.
ZEFFIX, FOR TREATMENT OF CHRONIC HEPATITIS B, APPROVED IN THE EUROPEAN UNION.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters